You are here: Industry Insights > mCRPC

News List

Novartis’ radioligand therapy granted US Breakthrough Therapy Designation pharmatimes
June 22, 2021
Swiss pharma company Novartis has scored a Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration for its investigational radioligand therapy Lu-PSMA-617.
Novartis prostate cancer drug gets FDA breakthrough designation pharmaceutical-technology
June 18, 2021
The FDA breakthrough designation is based on positive results from the Phase III VISION study of ¹⁷⁷Lu-PSMA-617.
Immunotherapy vaccine shows promise in prostate cancer patients europeanpharmaceuticalreview
March 31, 2021
The multi-targeted hAd5 immunotherapy vaccine was found to be safe and showed initial signs of efficacy in patients with advanced metastatic castration-resistant prostate cancer.
Erleada drug combination extends progression-free survival in prostate cancer trial europeanpharmaceuticalreview
February 10, 2021
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
BDR Pharma launches 80mg of Enzalutamide for prostate cancer treatment expresspharma
September 22, 2020
It reduces the pill burden and expected to increase the patient compliance.
Lynparza Demonstrated Overall Survival Benefit for Prostate Cancer in Trial americanpharmaceuticalreview
April 26, 2020
AstraZeneca and Merck announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) ...
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 americanpharmaceuticalreview
January 15, 2019
Leap Therapeutics announced an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Cancer Center at NYU Langone Health to study DKN-01......